• Alan D Kaye, Jolie A Boullion, Mariem Abdelsalam, Melanie A Green, Angela Nguyen, Ellie M MacDonald, Mehdi Dastgah, Corrado Ballaera, Shahab Ahmadzadeh, George Mychaskiw Ii, Sahar Shekoohi, and Christopher L Robinson.
• Departments of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA.
• Curr Pain Headache Rep. 2025 Jan 6; 29 (1): 1313.

Purpose Of ReviewKnee osteoarthritis (OA) is a gradual deterioration of articular cartilage characterized by pain and physical dysfunction. Although analgesic pharmacological agents are the first-line treatment for knee OA, they are not effective for all patients. In this study, we evaluate the efficacy of an intra-articular injection treatment using platelet-rich plasma (PRP) in reducing pain and improving functional ability.Recent FindingsFollowing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, this systematic review and meta-analysis (SR/MA) provides an updated overview for the role of PRP in knee OA treatment. Ten articles, published between 2016 and 2023, met the inclusion criteria and compared PRP treatment to a placebo control at six-month follow-up. A total of 9,409 potential studies were identified from a review of four different databases: PubMed (n = 4595), Cochrane (n = 4252), VHL (n = 112), and OpenSigle (n = 450). After the titles and abstracts and inclusion and exclusion criteria were considered, a total of 10 studies were analyzed. Although a significant improvement among PRP-treated groups in some studies was found, there was variability such as where the aforementioned scores appeared to worsen and some only demonstrated trends. Overall, PRP may be a promising treatment for symptomatic knee OA. However, further research is necessary to determine the efficacy of PRP in treating knee OA, with specific considerations for times at follow-up, frequency and dosage of injections, and comorbidities, which were unaccounted for in this SR/MA.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

11 keywords...

hide…